FOXP3 and myeloid sarcoma: Comparing all MS patients with HD, Population V containing naïve CD4+CD45RA+Foxp3− and TemRA cells was significantly lower in MS patients (21.48 ± 11.90%) than in HD (41.34 ± 14.07%) (p = 0.000001) (Fig. 2D).